NASDAQ:DAWN Day One Biopharmaceuticals (DAWN) Stock Price, News & Analysis $15.08 +0.07 (+0.47%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Day One Biopharmaceuticals Stock (NASDAQ:DAWN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DAWN alerts:Sign Up Key Stats Today's Range$14.97▼$15.3650-Day Range$13.30▼$15.0852-Week Range$9.67▼$18.07Volume889,711 shsAverage Volume924,225 shsMarket Capitalization$1.32 billionP/E RatioN/ADividend YieldN/APrice Target$35.71Consensus RatingModerate Buy Company OverviewDay One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Read More… This man beat out 16,000 stock pickers to earn the #1 spot (Ad)There are very few people in this world who are considered “the best” in their field. There are guys like Michael Jordan who is considered the best basketball player of all time… Or Warren Buffet who is considered the best Investor of all time… But we’ve just met a man who might be the best stock picker of all time… Right now, as we speak, he is currently ranked the #1 stock picker in North America.If you’d like to sit down with us, follow this link here. Day One Biopharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks55th Percentile Overall ScoreDAWN MarketRank™: Day One Biopharmaceuticals scored higher than 55% of companies evaluated by MarketBeat, and ranked 576th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingDay One Biopharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDay One Biopharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Day One Biopharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Day One Biopharmaceuticals are expected to decrease in the coming year, from ($1.68) to ($2.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Day One Biopharmaceuticals is -7.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Day One Biopharmaceuticals is -7.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDay One Biopharmaceuticals has a P/B Ratio of 3.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Day One Biopharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted26.42% of the float of Day One Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDay One Biopharmaceuticals has a short interest ratio ("days to cover") of 16, which indicates bearish sentiment.Change versus previous monthShort interest in Day One Biopharmaceuticals has recently increased by 3.77%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDay One Biopharmaceuticals does not currently pay a dividend.Dividend GrowthDay One Biopharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted26.42% of the float of Day One Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDay One Biopharmaceuticals has a short interest ratio ("days to cover") of 16, which indicates bearish sentiment.Change versus previous monthShort interest in Day One Biopharmaceuticals has recently increased by 3.77%, indicating that investor sentiment is decreasing. News and Social Media2.7 / 5News Sentiment0.88 News SentimentDay One Biopharmaceuticals has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Day One Biopharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for DAWN on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Day One Biopharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Day One Biopharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $689,072.00 in company stock.Percentage Held by InsidersOnly 8.40% of the stock of Day One Biopharmaceuticals is held by insiders.Percentage Held by Institutions87.95% of the stock of Day One Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Day One Biopharmaceuticals' insider trading history. Receive DAWN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address DAWN Stock News HeadlinesDay One Biopharmaceuticals (DAWN): Advancing Targeted Therapies for Pediatric GliomaOctober 17 at 12:49 AM | msn.comDay One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024October 16 at 8:30 AM | globenewswire.comHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.October 17, 2024 | Insiders Exposed (Ad)Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Up 5.2% After Analyst UpgradeOctober 10, 2024 | americanbankingnews.comDay One Biopharmaceuticals (NASDAQ:DAWN) Given New $33.00 Price Target at Needham & Company LLCOctober 9, 2024 | americanbankingnews.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOctober 9, 2024 | americanbankingnews.comDay One Biopharmaceutical (NASDAQ:DAWN) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comDAWN Jan 2025 12.500 callSeptember 25, 2024 | ca.finance.yahoo.comSee More Headlines DAWN Stock Analysis - Frequently Asked Questions How have DAWN shares performed this year? Day One Biopharmaceuticals' stock was trading at $14.60 on January 1st, 2024. Since then, DAWN stock has increased by 3.3% and is now trading at $15.08. View the best growth stocks for 2024 here. How were Day One Biopharmaceuticals' earnings last quarter? Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) announced its earnings results on Tuesday, July, 30th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.75) by $0.70. The company earned $8.19 million during the quarter, compared to analyst estimates of $0.90 million. When did Day One Biopharmaceuticals IPO? Day One Biopharmaceuticals (DAWN) raised $126 million in an initial public offering (IPO) on Thursday, May 27th 2021. The company issued 8,400,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Day One Biopharmaceuticals' major shareholders? Top institutional shareholders of Day One Biopharmaceuticals include Essex Investment Management Co. LLC (0.21%), Handelsbanken Fonder AB (0.03%) and Exchange Traded Concepts LLC (0.01%). Insiders that own company stock include Ai Day1 Llc, Xi LP Canaan, Samuel C Blackman, Michael Gladstone, Papanek Julie Grant, Julie Papanek Grant, Charles N York II, Jeremy Bender and Pharmaceutical Co Ltd Takeda. View institutional ownership trends. How do I buy shares of Day One Biopharmaceuticals? Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Day One Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Day One Biopharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and Tesla (TSLA). Company Calendar Last Earnings7/30/2024Today10/17/2024Next Earnings (Confirmed)10/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DAWN CUSIPN/A CIK1845337 Webdayonebio.com Phone650-484-0899FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$35.71 High Stock Price Target$44.00 Low Stock Price Target$24.00 Potential Upside/Downside+136.8%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-188,920,000.00 Net MarginsN/A Pretax Margin-2,025.49% Return on Equity-50.01% Return on Assets-44.15% Debt Debt-to-Equity RatioN/A Current Ratio4.09 Quick Ratio4.09 Sales & Book Value Annual Sales$8.19 million Price / Sales160.87 Cash FlowN/A Price / Cash FlowN/A Book Value$3.98 per share Price / Book3.79Miscellaneous Outstanding Shares87,390,000Free Float80,388,000Market Cap$1.32 billion OptionableOptionable Beta-1.51 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:DAWN) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.